NXTS vs ROIV vs VRTX Stock Comparison

Nexentis Technologies, Roivant Sciences and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
ROIV Roivant Sciences Ltd.
$39.53 +17.6% 1M +92.3% 1Y
Market cap
$28.25B
P/E
–
Revenue (TTM)
$41.08M
Div. yield
–
Biotechnology Healthcare
4 wins

Head to Head

8 decided of 12

Vertex Pharmaceuticals leads on 4 of the 12 questions below (Vertex Pharmaceuticals 4, Roivant Sciences 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSROIVVRTXLeader
Larger companyMarket capitalisation $329.72K $28.25B $136.22B VRTX
Cheaper on earningsLower P/E, profitable companies only 0.0x -82.0x 34.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 30.4x –
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +102.1% +10.5% ROIV
More profitableNet margin, trailing twelve months — -838.2% 30.7% VRTX
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA 0.8x — -0.4x VRTX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +92.3% +24.0% ROIV
Better 5-year returnAnnualised price return, 5 years -82.4%/yr +36.3%/yr +23.5%/yr ROIV
Less volatileAnnualised volatility, 1 year 235.4% 46.2% 29.5% VRTX
Higher overall scoreMean of the five percentile scores vs peers 18/100 78/100 73/100 ROIV

Percentile Scorecard

NXTSROIVVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSROIVVRTX
Valuation 7 #612 of 660 69 #207 of 660 77 #152 of 660
Growth 6 #585 of 619 86 #88 of 619 46 #333 of 619
Profitability 22 #462 of 595 51 #294 of 595 93 #40 of 595
Financial Health 38 #423 of 683 93 #47 of 683 55 #311 of 683
Shareholder Returns – 92 #40 of 459 92 #37 of 459
Overall 18 78 73
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ROIV ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSROIVVRTXSPY
1 month +229.2%+17.6%+8.0% -2.0%
3 months +12.0%+9.2%+6.5% -2.8%
6 months -52.0%+35.0%+23.3% +2.0%
Year to date -81.8%+82.2%+18.8% +10.6%
1 year -90.3%+92.3%+24.0% +12.2%
3 years -99.6%+325.1%+45.6% +68.1%
3 years, per year -84.2%+62.0%+13.3% +18.9%
5 years -100.0%+370.6%+187.6% +61.4%
5 years, per year -82.4%+36.3%+23.5% +10.1%
10 years -100.0%—+485.4% +248.5%
10 years, per year -61.8%—+19.3% +13.3%

Risk

MeasureNXTSROIVVRTXSPY
Volatility, 1Y 235.4%46.2%29.5% 13.6%
Downside volatility, 1Y 158.4%33.3%26.1% 13.9%
Beta vs S&P 500, 1Y 4.331.100.43 1.00
Return / volatility, 1Y -0.382.000.81 0.90
Max drawdown, 5Y -100.0%-79.2%-29.1% -25.4%
From 52-week high -90.5%-5.5%-3.6% -3.2%
52-week high $22.54$41.85$558.71 $779.14
52-week low $0.48$20.10$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSROIVVRTX
P/E now vs peer median 0.0xmedian 17.0x -83.0xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 696.3xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x -43.9xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x -858.0xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x 6.2xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median 0.00median 0.43 -2.97median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSROIVVRTX
Revenue -$8.94M $41.08M $12.95B
Gross profit – $36.43M $11.08B
Operating income -$10.88M -$557.96M $4.30B
Net income -$16.14M -$440.18M $3.98B
Free cash flow -$4.50M -$33.34M $3.20B
R&D $798.00K $712.09M $4.25B
EPS (diluted) $-98.21 $-0.48 $15.58
Cash & equivalents $7.62M $1.64B $4.98B
Total debt $422.00K – $4.50B
Shares (diluted) 163.23K 722.75M 255.20M
Enterprise value -$25.11M $11.38B $103.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSROIVVRTX
P/E 0.0x -83.0x 34.3x
P/FCF -0.1x -858.0x 42.6x
P/Operating cash flow -0.1x -786.2x 37.0x
P/S 0.0x 696.3x 10.5x
P/B 0.2x 6.2x 6.5x
P/Tangible book -0.2x 6.2x 11.0x
EV/EBITDA 0.8x -43.9x 29.7x
EV/EBIT 0.7x -43.7x 31.3x
EV/Revenue 0.9x 593.9x 10.4x
EV/FCF 1.8x -731.8x 42.1x
EV/Operating cash flow 1.8x -670.5x 36.5x
PEG (3Y EPS CAGR) 0.00 -2.97 6.39

Growth

14 metrics
MetricNXTSROIVVRTX
Revenue growth (1Y) -4,238% 102.1% 10.5%
Revenue CAGR (3Y) -182.9% 0.9% 10.3%
Gross profit growth (1Y) – 85.9% 9.5%
Gross profit CAGR (3Y) – -1.3% 9.3%
Operating income growth (1Y) -127.3% 51.5% 7.8%
Operating income CAGR (3Y) -23.5% 12.5% 3.5%
Net income growth (1Y) -70.1% 15.8% 8.2%
Net income CAGR (3Y) -42.2% 25.4% 4.6%
EPS growth (1Y) -666.2% 13.2% 9.2%
EPS CAGR (3Y) -52.0% 28.0% 5.4%
Operating cash flow growth (1Y) -62.8% 95.3% -0.6%
Operating cash flow CAGR (3Y) -0.4% 65.0% -5.5%
Free cash flow growth (1Y) -65.5% 95.7% -4.0%
Free cash flow CAGR (3Y) -0.7% 66.0% -8.7%

Profitability

14 metrics
MetricNXTSROIVVRTX
Gross margin – 88.7% 85.5%
EBITDA margin – -1,352% 35.1%
Operating margin – -1,358% 33.2%
Pretax margin – -723.4% 36.7%
Net margin – -838.2% 30.7%
FCF margin – -81.2% 24.7%
Operating cash flow margin 49.6% -88.6% 28.5%
Return on equity -218.6% -8.1% 19.3%
Return on assets -92.0% -7.5% 13.2%
Return on invested capital – – –
Return on capital employed -73.7% -11.5% 17.2%
Asset turnover -0.5x 0.0x 0.4x
Cash conversion (OCF / net income) 0.3x 0.1x 0.9x
Stock comp / revenue -11.0% 819.9% 5.2%

Financial Health

11 metrics
MetricNXTSROIVVRTX
Debt / assets 2.3% – 13.7%
Debt / equity 0.2x – 0.2x
Net debt / EBITDA 0.8x – -0.4x
Debt / FCF -0.1x – 1.4x
Liabilities / assets 89.8% 7.6% 36.1%
Equity / assets 10.2% 92.4% 63.9%
Interest coverage – – 93.0x
Current ratio 3.7x 15.6x 2.3x
Quick ratio 3.2x 15.0x 1.7x
Cash ratio 3.2x 15.0x 1.3x
Altman Z-score -6.11 45.44 8.70

Shareholder Returns

7 metrics
MetricNXTSROIVVRTX
Dividend yield – – –
Net buyback yield -2,794% 0.4% 0.7%
Shareholder yield -2,794% 0.4% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSROIVVRTX
Forward P/E – – 30.4xFY2026
EPS, next fiscal year – $-1.22FY2026 $17.71FY2026
EPS growth, next FY – – -3.7%FY2026
EPS growth, the year after – – +20.2%
Revenue, next fiscal year – $158.10MFY2026 $12.68BFY2026
Revenue growth, next FY – +1,814.0%FY2026 +5.9%FY2026
Revenue growth, the year after – +317.0% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSROIVVRTX
Held by institutions – 77.0% 95.1%
Institutions holding – 500 1,747
Change in shares held, QoQ – +5.1% +3.9%
Institutions buying – 304 904
Institutions selling – 138 605
Buyers to sellers – 2.20 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSROIVVRTX
NXTS 1.00 0.10 0.05
ROIV 0.10 1.00 0.24
VRTX 0.05 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, ROIV and VRTX?

Vertex Pharmaceuticals (VRTX) is the largest by market capitalisation: Nexentis Technologies (NXTS) $329.72K, Roivant Sciences (ROIV) $28.25B, Vertex Pharmaceuticals (VRTX) $136.22B.

Which company is growing faster?

Roivant Sciences (ROIV) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Roivant Sciences (ROIV) +102.1%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Roivant Sciences (ROIV) -838.2%, Vertex Pharmaceuticals (VRTX) 30.7%).

Which stock has performed better?

Over the past year Roivant Sciences (ROIV) returned the most: Nexentis Technologies (NXTS) -90.3%, Roivant Sciences (ROIV) +92.3%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Roivant Sciences (ROIV) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Roivant Sciences (ROIV) +36.3%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Vertex Pharmaceuticals (VRTX) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Roivant Sciences (ROIV) 46.2%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, ROIV and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Vertex Pharmaceuticals (VRTX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.